Israeli Institutions Profit From AI Firm Anthropic Ahead of IPO
Translated & summarized from Mako by baba
Israeli institutional investors Migdal and Clal have reported substantial unrealized profits on their investments in AI firm Anthropic, which is nearing an IPO. Their stakes, funded by client savings, are valued between 1.8 and 3.8 times their initial investment. The company is reportedly valued at $2 trillion ahead of its stock market debut, with its prospectus detailing both revolutionary potential and significant risks.
The story in 5 lines · by baba
- Israeli firms Migdal and Clal hold Anthropic investments valued significantly higher than their initial cost.
- Anthropic is preparing for an IPO, with market speculation placing its valuation at $2 trillion.
- Migdal's investments show a return of up to 3.8 times the cost, while Clal's show up to 1.8 times.
- Valuation differences between the two firms are attributed to the timing of their asset revaluations.
- Anthropic's prospectus warns of risks including potential misuse for weapons development.
Two Israeli institutional investors, Migdal and Clal, have seen significant unrealized gains on their investments in the artificial intelligence company Anthropic, which is preparing for an initial public offering (IPO). The companies invested tens of millions of dollars of their clients' savings into Anthropic through investment funds managed by ICONIQ. As of the end of June, Migdal held stakes valued at approximately $192 million, while Clal held stakes valued at about $122 million. These figures represent returns of 1.8 to 3.8 times the initial investment for the respective holdings.
Migdal's investments, made in August 2025 and January, are currently valued at $54 million and $62 million, respectively, reflecting multiples of 3.8 and 2.2 times their cost. An additional holding is valued at $75 million. Clal invested approximately $47 million in the same August 2025 fund, now valued at $82 million, a 1.8 multiple. Their investment from May, around $40 million, is still recorded at cost, resulting in a $35 million unrealized gain.
The difference in valuation between Migdal and Clal stems from the timing of their asset revaluation. Migdal updated its holdings to reflect Anthropic's Series H funding round, which valued the company at approximately $589 per share. Clal's latest valuation is based on its May assessment, reflecting a price closer to its Series G round ($259 per share). If Clal had revalued its holdings at Migdal's rate, its stake would be worth an additional $100 million.
Anthropic has filed its IPO prospectus, with market speculation valuing the company at around $2 trillion. The prospectus highlights both the potential of Anthropic's technology, which could aid in developing cures for diseases like cancer, and significant risks. These risks include the potential misuse of its models for developing biological or chemical weapons and the possibility of autonomous systems causing harm. The company holds approximately $131.7 billion in cash and short-term investments.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
